Industry Tutorial: Standardizing High-content Immune Profiling in Translational and Clinical Research: Case Studies

In 2017, the NCI established four Cancer Immune Monitoring and Analysis Centers (CIMACs), which perform standardized, state-of-the-art immunological assays for selected cancer immunotherapy clinical trials. One such assay is high-content cytometric immunophenotyping with CyTOF®, for which the four CIMACs performed cross-site harmonization. Holden Maecker will detail the results and lessons learned from those harmonization efforts, as well as plans for using the Maxpar® Direct™ Immune Profiling Assay™, a standardized, dry-format, high-parameter immunophenotyping assay for mass cytometry, in future CIMAC trials and other studies.

CyTOF XT™ and the Hyperion+™ Imaging System provide powerful tools for deep immune profiling of cell suspensions and tissue that are easy to use and enable the needed throughput and data quality required for large translational and clinical research studies. Andrew Quong will present case studies detailing how the Maxpar Direct Immune Profiling Assay was used for these large studies following subjects over time and at multiple sites of sample acquisition. In addition, case studies exploring the highly complex tissue microenvironment and its impact in infectious disease and cancer will be presented.